Navigation Links
AMRI Announces 3-Year Extension of Insourcing Contract
Date:1/12/2016

ALBANY, N.Y., Jan. 12, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) is pleased to announce the extension of a key insourcing relationship with a major pharmaceutical company designed to accelerate their chemistry and drug discovery efforts. The original insourcing collaboration, which commenced in 2011, is being extended significantly beyond its original termination date of December 2018 to December 31, 2021.

"Insourcing relationships provide the benefit of accelerating drug discovery, drug product and manufacturing efforts by maximizing the real-time exchange of scientific information and enabling scientists to rapidly adapt to changing project needs," said Michael P. Trova, Senior Vice President, Chemistry, AMRI. "We find these relationships are mutually beneficial and will be an important key to the long-term development and success of AMRI's DDS business unit. We look forward to finding new ways to deepen and extend these unique arrangements."

"The insourcing model is a fusion of the best elements of external outsourcing and in-house R&D activities," said Christopher Conway, Senior Vice President of Discovery and Development Services, AMRI. "With expertise in managing high performing groups of scientists, AMRI developed this business model in order to embed its own scientists into the customer's facility, allowing the customer to cost-effectively leverage their underutilized laboratory space and resources."

About Albany Molecular Research Inc.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, hormones, cytotoxic compounds and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations.

Forward-Looking Statements 
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties.  These statements include, but are not limited to, statements regarding the term or extension of customer contracts, the benefits to be derived by the company from its insourcing or other customer relationships, and the potential impact on the long-term results of the company's business unit(s).  Readers should not place undue reliance on our forward-looking statements.  The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company the company may not be able to predict and may not be within the company's control.  Factors that could cause such differences include, but are not limited to, the ability of the company to hire and retain qualified scientists to provide insourcing services, the risk of a decrease in customers' demand for the company's services, including but not limited to early termination of customer contracts, as well as those risks discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 16, 2015, and the company's other SEC filings.

For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

 


'/>"/>
SOURCE AMRI
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. HeartWare International Provides Corporate Updates And Announces Preliminary Revenue For Fourth Quarter 2015
2. Mauna Kea Technologies Announces the Appointment of Joseph DeVivo as a Non-Executive Director
3. KaloBios Pharmaceuticals, Inc. Announces Board Changes and New Appointments
4. Bio2 Technologies, Inc. Announces Receipt of FDA 510(k) Clearance for a Fusion Implant System for Extremities Surgery
5. NuMedii, Inc. Announces New Indications Discovery Collaboration With Astellas
6. Medicure Announces Preliminary Revenue For Fiscal 2015
7. Worlds Largest Materials Science Catalog Announces Launch Of New Website
8. Agena Bioscience Announces the Expansion of its Headquarters in San Diego, California, to Better Serve its Growing Customer Base
9. Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2015 Revenue
10. Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002
11. Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... disease diagnostics with genomics, announced today the results of an ongoing clinical study ... showed that the Karius® Test, a non-invasive blood test that detects pathogen cell-free ...
(Date:12/10/2018)... (PRWEB) , ... December 10, 2018 , ... ... are pleased to announce the formation of Parkview Dental Partners (“Parkview Dental”), a ... Dr. Kenneth Liszewski, founder of BayView Dental, a group dental practice comprised of ...
(Date:12/8/2018)... (PRWEB) , ... December 07, 2018 , ... ... eye care practice management organizations in the nation, and Southwestern Eye Center, an ... Eye Center. The affiliation of the two businesses will improve the quality of ...
Breaking Medicine Technology:
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... designed to appear more modern and approachable in their community. Delia Associates created ... to provide treatment for those dealing with substance abuse in the greater Hunterdon ...
(Date:12/13/2018)... YORK (PRWEB) , ... December 13, 2018 , ... Researchers ... of two classes of drugs that induces the highest rate of proliferation ever observed ... is an important step toward a diabetes treatment that restores the body’s ability to ...
(Date:12/13/2018)... ... ... Mediaplanet today announces the launch of this December’s issue of “Transplants: The Gift ... to sign up as an organ and/or whole-body donor for the 120,000 people in ... organ donor can save up to 8 lives, however, an average of 22 people ...
(Date:12/13/2018)... ... December 13, 2018 , ... Individuals who are interested ... to win a full-ride scholarship offered by Dr. Kami Hoss of Howard Healthcare Academy. ... The full-ride scholarship would enable a student to become a registered dental assistant for ...
(Date:12/10/2018)... ... 10, 2018 , ... Loma Linda University School of Public Health ... found a link with freight-railyard pollution to asthma-related emergency room visits in children. The ... large-scale railyard study is a follow-up to the i nitial study of ...
Breaking Medicine News(10 mins):